Report cover image

Middle East Small Molecule Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Clinical, Commercial), By Service, By Therapeutic Area (Oncology, Infectious Diseases), By End-use, By Country, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Dec 02, 2025
Length 180 Pages
SKU # GV20723718

Description

Middle East Small Molecule Contract Manufacturing Market Summary

The Middle East small molecule contract manufacturing market size was estimated at USD 4.07 billion in 2024 and is projected to reach USD 8.90 billion by 2033, growing at a CAGR of 9.24% from 2025 to 2033. The market growth is driven by increasing prevalence of chronic diseases, growing emphasis on R&D in the Middle East’s pharmaceutical sector, expanding costs for establishing and maintaining in-house manufacturing facilities and stringent regulatory requirements.

Some other factors contributing to segment growth are rising government initiatives to localize pharmaceutical production, growing generic drug development, and increasing partnerships among regional manufacturers and global CDMOs. In addition, the growing expansion of GMP-compliant facilities, improved logistics infrastructure, and strong investment from Gulf countries in building advanced pharmaceutical clusters are expected to enable faster, cost-effective, and high-quality production of small molecules. Such factors are expected to drive the market growth over the estimated time period.

The increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer in the Middle East has caused a surge in demand for pharmaceutical products. A study published in August 2025 highlighted that diabetes mellitus is the most common chronic condition in Saudi Arabia, ranking first in three out of five studies reporting disease-specific patterns. Overall, multimorbidity prevalence ranged from 7.1% to 77.6%, with women, particularly older adults, experiencing notably higher rates, underscoring the growing burden of chronic diseases in the population. The rising disease conditions are putting pressure on domestic pharmaceutical companies to scale up production, which in turn is contributing to the outsourcing of manufacturing to contract manufacturing organizations. Thus, the small molecule contract manufacturing market is experiencing growth as companies utilize specialized expertise, advanced facilities, and cost efficiencies offered by contract manufacturing to meet the growing patient needs and ensure the timely availability of essential medications across the region.

In addition, the growing emphasis on R&D in the Middle East’s pharmaceutical sector has caused companies to seek partnerships with specialized contract manufacturers. Besides, outsourcing small molecule synthesis and formulation enables companies to accelerate drug development timelines, access advanced technologies, and utilize scientific expertise without significant capital investment. For instance, in July 2025, Saudi Arabia invited Indian pharmaceutical and medical device contract manufacturing companies to explore strategic partnerships and acquisitions, promoting the localization of APIs and small molecule manufacturing to enhance healthcare resilience, reduce import dependency, and support the objectives of Vision 2030. This increased collaboration with contract manufacturing drives the growth of the small molecule contract manufacturing industry, enabling companies to bring innovative therapies to market more quickly, reduce time-to-market, and maintain competitiveness in an increasingly dynamic and regulated pharmaceutical environment.

Furthermore, the increasing costs of establishing and maintaining in-house manufacturing facilities have led pharmaceutical companies to seek more efficient alternatives. By outsourcing small molecule production to contract manufacturers, companies reduce capital expenditures, operational risks, and compliance burdens. This shift allows companies to focus on R&D and commercialization while benefiting from the economies of scale and advanced technological capabilities of contract manufacturing units. As a result, the demand for small molecule contract manufacturing rises, enabling faster production cycles, improved product quality, and enhanced competitiveness in the regional pharmaceutical market.

Middle East region has increasingly stringent regulatory requirements for pharmaceutical manufacturing, including adherence to GMP, ISO, and regional health authority guidelines. This has caused domestic companies to face challenges in maintaining compliance in-house, prompting them to outsource production to specialized contract manufacturers. Moreover, the contract manufacturing units offer expertise in navigating complex regulatory frameworks, ensuring quality control, documentation, and timely approvals. Thus, most pharmaceutical companies are focusing on reducing compliance risks, avoiding production delays, and driving innovation, which further propels the small molecule contract manufacturing industry across the region.

Middle East Small Molecule Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East small molecule contract manufacturing market report based on type, service, therapeutic area, end-use, and country.
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Clinical
  • Commercial
  • Service Outlook (Revenue, USD Million, 2021 - 2033)
  • API Manufacturing
  • Traditional API
  • HP-API
  • Controlled Substances/Specialty API
  • Finished Dose Formulations Manufacturing
  • Oral Solid
  • Injectables
  • Topical
  • Others
  • Packaging & Labelling
  • Others
  • Therapeutic Area Outlook (Revenue, USD Million, 2021- 2033)
  • Oncology
  • Cardiovascular Disease
  • Neurological Disorders
  • Infectious Diseases
  • Metabolic Disorders
  • Hormonal Disorders
  • Autoimmune Diseases
  • Gastrointestinal Disorders
  • Respiratory Diseases
  • Ophthalmology
  • Hematological Disorders
  • Others
  • Autoimmune/Inflammation
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Large Pharmaceutical Companies
  • Small & Medium Pharmaceutical Companies
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Middle East Small Molecule Contract Manufacturing
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar
  • Rest of Middle East
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

180 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Type
1.2.2. Service
1.2.3. Therapeutic Area
1.2.4. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Middle East Small Molecule Contract Manufacturing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Pharmaceutical Demand and Chronic Disease Burden
3.2.1.2. Increasing Focus on R&D and Innovation
3.2.1.3. Cost-Effectiveness and Operational Efficiency
3.2.1.4. Stringent Regulatory Compliance and Quality Standards
3.2.2. Market Restraint Analysis
3.2.2.1. Limited Skilled Workforce and High Operational Costs
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Market Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL by SWOT Analysis
Chapter 4. Middle East Small Molecule Contract Manufacturing Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Small Molecule Contract Manufacturing Market: Type Movement Analysis
4.3. Middle East Small Molecule Contract Manufacturing Market Estimates and Forecasts, by Type, 2021 - 2033 (USD Million)
4.4. Clinical
4.4.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Commercial
4.5.1. Commercial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Middle East Small Molecule Contract Manufacturing Market: Service Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East Small Molecule Contract Manufacturing Market: Service Movement Analysis
5.3. Middle East Small Molecule Contract Manufacturing Market Estimates and Forecasts, by Service, 2021 - 2033 (USD Million)
5.4. API Manufacturing
5.4.1. API Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.2. Traditional API
5.4.2.1. Traditional API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.3. HP-API
5.4.3.1. HP-API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4.4. Controlled Substances/Specialty API
5.4.4.1. Controlled Substances/Specialty API Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Finished Dose Formulations Manufacturing
5.5.1. Finished Dose Formulations Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.2. Oral Solid
5.5.2.1. Oral Solid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.3. Injectables
5.5.3.1. Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.4. Topical
5.5.4.1. Topical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5.5. Others
5.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Packaging & Labelling
5.6.1. Packaging & Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Middle East Small Molecule Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East Small Molecule Contract Manufacturing Market: Therapeutic Area Movement Analysis
6.3. Middle East Small Molecule Contract Manufacturing Market Estimates and Forecasts, by Therapeutic Area, 2021 - 2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Cardiovascular Disease
6.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Neurological Disorders
6.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Infectious Diseases
6.7.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Metabolic Disorders
6.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Hormonal Disorders
6.9.1. Hormonal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.10. Autoimmune Diseases
6.10.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.11. Gastrointestinal Disorders
6.11.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.12. Respiratory Diseases
6.12.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.13. Ophthalmology
6.13.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.14. Hematological Disorders
6.14.1. Hematological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.15. Others
6.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Middle East Small Molecule Contract Manufacturing Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Middle East Small Molecule Contract Manufacturing Market: End Use Movement Analysis
7.3. Middle East Small Molecule Contract Manufacturing Market Estimates and Forecasts, by End Use, 2021 - 2033 (USD Million)
7.4. Large Pharmaceutical Companies
7.4.1. Large Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Small & Medium Pharmaceutical Companies
7.5.1. Small & Medium Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Middle East Small Molecule Contract Manufacturing Market: Regional Estimates & Trend Analysis
8.1. Regional Outlook
8.2. Middle East Small Molecule Contract Manufacturing Market: Regional Movement Analysis
8.3. Middle East Small Molecule Contract Manufacturing Market Estimates and Forecasts, by region, 2021 - 2033 (USD Million)
8.3.1. Saudi Arabia
8.3.1.1. Key Country Dynamics
8.3.1.2. Competitive Scenario
8.3.1.3. Regulatory Framework
8.3.1.4. Saudi Arabia Small Molecule Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. UAE
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. UAE Small Molecule Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.3. Kuwait
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Kuwait Small Molecule Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.4. Oman
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. Oman Small Molecule Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.5. Qatar
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Qatar Small Molecule Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.1.1. Market Leaders
9.1.2. Emerging Players
9.2. Market Share/Assessment Analysis, 2024 (Company Heat Map Analysis)
9.3. Company Profiles
9.3.1. Neopharma
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Tabuk Pharmaceuticals
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. SPIMACO
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Sudair Pharma
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. MISA
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. AHT Health SARL
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Abdi Ibrahim Remede Pharma
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Saidal
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. El Kendi
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Julphar
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Service Benchmarking
9.3.10.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us